Information updates

Parliamentary Inquiry into Allergies and Anaphylaxis

19 November 2019

There were two hearings this week for the Parliamentary Inquiry into Allergies and Anaphylaxis, in Melbourne on Monday 18th November 2019 (10am-5pm) and in Sydney on Tuesday 19th November 2019 (9.30-4.30pm). Hansard records of the hearings will soon be on the APH website

ASCIA lodged a submission to the Inquiry on 24 October 2019 and an opening statement was presented by the ASCIA President, Dr Brynn Wainstein at the Tuesday hearing, conducted by the House of Representatives Standing Committee on Health, Aged Care and Sport committee. Both documents can be viewed on the ASCIA website

More than twenty ASCIA members were involved as witnesses in the Sydney and Melbourne hearings, including:

  • Four ASCIA Council members (Dr Lara Ford, Dr Preeti Joshi, Dr Brynn Wainstein and Dr Melanie Wong).
  • Four past ASCIA Presidents - Professor Tony Basten AO, Professor Jo Douglass, Professor Connie Katelaris AM and Dr Melanie Wong.

Two ASCIA staff members (Jill Smith, ASCIA CEO and Sandra Vale, National Allergy Strategy Manager) were also involved as witnesses for the Sydney hearing. 

The ASCIA submission focuses on the following ten key issues: 

  1. Support is required for quality allergy and anaphylaxis educational and training resources for patients, carers and health professionals.
  2. Support is required for quality, evidence-based allergy and anaphylaxis education and training for all health professionals.
  3. Improved access to timely, equitable and quality care for patients with allergic disease is needed.
  4. Improved access to skin testing reagents for allergy diagnosis by clinical immunology/allergy specialists is needed.
  5. A specific food allergen challenge MBS item number is needed.
  6. A specific drug allergen challenge MBS item number is needed.
  7. Improved access to evidence-based and cost-effective treatments is needed.
  8. Support is required for further research into all allergic diseases.
  9. Support is required for further research into food allergy treatments including oral immunotherapy.
  10. National anaphylaxis and drug allergy registers do not exist.

Individuals or organisations wish to make a submission the deadline has recently been extended to Friday 29 November 2019 and hearings will be held in other cities.

For details go to    

Mod ASCIA Member
Donate to AIFA
go to NAS website
ASCIA Member Login
ASCIA Update

Information for the community about allergic diseases, immunodeficiencies and other immune diseases.
See latest edition here...
Join our mailing list:


ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.